Literature DB >> 32235387

Progress and Prospects on Vaccine Development against SARS-CoV-2.

Jinyong Zhang1, Hao Zeng1, Jiang Gu1, Haibo Li1, Lixin Zheng2, Quanming Zou1.   

Abstract

In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.

Entities:  

Keywords:  SARS-CoV-2; adjuvant; animal model; vaccine

Year:  2020        PMID: 32235387     DOI: 10.3390/vaccines8020153

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  84 in total

1.  Promise and challenges in the development of COVID-19 vaccines.

Authors:  Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2020-07-23       Impact factor: 3.452

Review 2.  The COVID-19 pandemic and the potential treatment of the novel coronavirus SARS-CoV-2.

Authors:  Shilei Wang; Jinlei Ye; Zhichao Kang; Hongmei Peng; Vienna Mackey; Lichun Sun
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 3.  SARS-CoV-2 vaccine candidates in rapid development.

Authors:  Lifeng Li; Pengbo Guo; Xiaoman Zhang; Zhidan Yu; Wancun Zhang; Huiqing Sun
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

Review 4.  Coronavirus disease 2019 (COVID-19) vaccines: A concise review.

Authors:  Lakshman Perera Samaranayake; Chaminda Jayampath Seneviratne; Kausar Sadia Fakhruddin
Journal:  Oral Dis       Date:  2021-05-15       Impact factor: 4.068

Review 5.  Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.

Authors:  Idris Nasir Abdullahi; Anthony Uchenna Emeribe; Hafeez Aderinsayo Adekola; Sharafudeen Dahiru Abubakar; Amos Dangana; Halima Ali Shuwa; Sunday Theophilus Nwoba; Jelili Olaide Mustapha; Muyideen Titilope Haruna; Kafayat Adepeju Olowookere; Olawale Sunday Animasaun; Charles Egede Ugwu; Solomon Oloche Onoja; Abdullahi Sani Gadama; Musa Mohammed; Isa Muhammad Daneji; Dele Ohinoyi Amadu; Peter Elisha Ghamba; Nkechi Blessing Onukegbe; Muhammad Sagir Shehu; Chiladi Isomah; Adamu Babayo; Abdurrahman El-Fulaty Ahmad
Journal:  Hum Vaccin Immunother       Date:  2020-09-16       Impact factor: 3.452

6.  Healthcare Workers' Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study.

Authors:  Leena R Baghdadi; Shatha G Alghaihb; Alanoud A Abuhaimed; Dania M Alkelabi; Rawan S Alqahtani
Journal:  Vaccines (Basel)       Date:  2021-05-06

Review 7.  An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system.

Authors:  Padmalochan Hembram
Journal:  Bull Natl Res Cent       Date:  2021-07-09

Review 8.  Inside the story about the research and development of COVID-19 vaccines.

Authors:  Shrina P Patel; Gayatri S Patel; Jalpa V Suthar
Journal:  Clin Exp Vaccine Res       Date:  2021-05-31

9.  New insights into the catalytic mechanism of the SARS-CoV-2 main protease: an ONIOM QM/MM approach.

Authors:  Henrique S Fernandes; Sérgio F Sousa; Nuno M F S A Cerqueira
Journal:  Mol Divers       Date:  2021-06-24       Impact factor: 3.364

Review 10.  An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.

Authors:  Hamid Motamedi; Marzie Mahdizade Ari; Shirin Dashtbin; Matin Fathollahi; Hadi Hossainpour; Amirhoushang Alvandi; Jale Moradi; Ramin Abiri
Journal:  Int Immunopharmacol       Date:  2021-05-06       Impact factor: 5.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.